RT Journal Article
SR Electronic
T1 Case finding of early pregnancies at risk of preeclampsia using maternal blood leptin/ceramide ratio: multi-omics discovery and validation from a longitudinal study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.17.20248418
DO 10.1101/2020.12.17.20248418
A1 Qianyang Huang
A1 Shiying Hao
A1 Jin You
A1 Xiaoming Yao
A1 Zhen Li
A1 James Schilling
A1 Zhen Li
A1 Sheeno Thyparambil
A1 Wei-li Liao
A1 Xin Zhou
A1 Lihong Mo
A1 Subhashini Ladella
A1 David Fan
A1 John C. Whitin
A1 Harvey J. Cohen
A1 Doff B. McElhinney
A1 Ronald J. Wong
A1 Gary M. Shaw
A1 David K. Stevenson
A1 Karl G. Sylvester
A1 Xuefeng B. Ling
YR 2021
UL http://medrxiv.org/content/early/2021/01/07/2020.12.17.20248418.abstract
AB Objective To evaluate whether longitudinal measurements of serological adipokines and sphingolipids can predict preeclampsia early in gestation.Design Retrospective multi-omics discovery and longitudinal validation.Setting Maternity units in two US hospitals.Methods A multi-omics approach integrating genomic and lipidomic discoveries was employed to identify leptin (Lep) and ceramide (Cer) as novel PE early gestational biomarkers. The levels of placental growth factor (PlGF), soluble fms-like tyrosine kinase (sFlt-1), Lep, and Cer in maternal sera were then determined by enzyme-linked immunosorbent (ELISA) and liquid chromatography-tandem mass spectrometric (LC/MS/MS) assays.Main outcome measures Interval from positive prediction to confirmative diagnosis.Results Genomic meta-analysis compiled six PE placental cohorts with 78 PE and 95 non-PE control placentas. The Testing Cohort included sera from 7 non-PE and 8 PE women collected at confirmatory diagnosis. The Validation Cohort included sera from 20 non-PE and 20 PE women collected longitudinally through gestation. Our findings revealed a marked elevation of maternal serum Leptin/Ceramide (d18:1/25:0) ratio from early gestation (a median of 23 weeks) when comparing later PE-complicated with uncomplicated pregnancies. The maternal Lep/Cer (d18:1/25:0) ratio significantly outperformed the established sFlt-1/PlGF ratio in predicting PE for sensitivity (85% vs. 40%), positive predictive value (89% vs. 42%), and AUC (0.92 vs. 0.52) from 5 to 25 weeks of gestation.Conclusions Non-invasive longitudinal assessment by serological evaluation of Lep/Cer (d18:1/25:0) ratio can case find early pregnancies at risk of preeclampsia, outperforming sFlt-1/PlGF ratio test.Tweetable abstract Non-invasive longitudinal assessment by serological evaluation of Lep and Cer ratio can predict preeclampsia early in gestation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study approval was obtained from ProMedDX Inc. and the Institutional Review Board at Stanford University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analyzed in this study are available upon request to the corresponding author.ACCAcetyl-CoA carboxylaseAUCArea Under the CurveAMPKK/AMPKAMP-activated protein kinaseBMIBody Mass IndexCerCeramideCIConfidence IntervalDHCerDihydroceramideELISAEnzyme-Linked Immunosorbent AssayGEOGene Expression OmnibusLepLeptinLC/MS/MSLiquid Chromatography-Tandem Mass SpectrometryNPVNegative Predictive ValuePlGFPlacental Growth FactorPPVPositive Predictive ValuePEPreeclampsiasFlt-1Soluble fms-Like Tyrosine KinaseWkWeek